Article
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.
Future oncology (London, England) - 1 Jan 2023
Cheema Parneet, Cho Byoung Chul, Freitas Helano, Provencio Mariano, Chen Yuh Min, Kim Sang-We, Wu Yi-Long, Passaro Antonio, Martin Claudio, Tiseo Marcello, Chang Gee-Chen, Park Keunchil, Solomon Benjamin, Burghuber Otto, Laskin Janessa, Wang Ziping, Lee Sung Yong, Hu Yanping, Vansteenkiste Johan, Zhang He-Long, Hanrahan Emer, Geldart Thomas, Taylor Rosemary, Servidio Leslie, Li Jingyi, Marinis Filippo de
Abstract excerpt
Aim: Report the final analysis from ASTRIS, the largest real-world study of second-/later-line osimertinib in advanced/metastatic EGFR T790M non-small-cell lung cancer (NSCLC). Methods: Patients with advanced/metastatic EGFR T790M NSCLC and prior EGFR-TKI treatment, received once-daily osimertinib 80 mg. Primary end point: overall survival (OS); secondary end points: progression-free survival (PFS),...
Topics
Join the communities discussing this publication.